Somatostatin Receptor Type 2 - Pipeline Review, H2 2019
Somatostatin Receptor Type 2 - Pipeline Review, H2 2019
SUMMARY
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) pipeline Target constitutes close to 13 molecules. The latest report Somatostatin Receptor Type 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Somatostatin receptor type 2 is a protein that encoded by the SSTR2 gene. Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. SSTR2 is expressed in highest levels in cerebrum and kidney. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 6 and 2 respectively. Report covers products from therapy areas Hormonal Disorders, Oncology, Metabolic Disorders, Gastrointestinal, Genetic Disorders and Undisclosed which include indications Acromegaly, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion (Cushing Disease), Pituitary Tumor, Gastric Motility Disorder, Hypoglycemia, Ileus (Intestinal Obstruction), Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma (Glomus Jugulare Tumor), Pheochromocytoma, Polycystic Kidney Disease, Type 2 Diabetes and Unspecified.
Furthermore, this report also reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) pipeline Target constitutes close to 13 molecules. The latest report Somatostatin Receptor Type 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Somatostatin receptor type 2 is a protein that encoded by the SSTR2 gene. Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. SSTR2 is expressed in highest levels in cerebrum and kidney. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 6 and 2 respectively. Report covers products from therapy areas Hormonal Disorders, Oncology, Metabolic Disorders, Gastrointestinal, Genetic Disorders and Undisclosed which include indications Acromegaly, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion (Cushing Disease), Pituitary Tumor, Gastric Motility Disorder, Hypoglycemia, Ileus (Intestinal Obstruction), Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma (Glomus Jugulare Tumor), Pheochromocytoma, Polycystic Kidney Disease, Type 2 Diabetes and Unspecified.
Furthermore, this report also reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)
- The report reviews Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 2 (SRIF1 or SSTR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Overview
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Companies Involved in Therapeutics Development
Amryt Pharma Plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Enteris BioPharma Inc
GlyTech Inc
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Takeda Pharmaceutical Co Ltd
Tiburio Therapeutics Inc
Zucara Therapeutics Inc
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Drug Profiles
AP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-00808 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-01941 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Edotreotide Labeled Yttrium 90 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR2 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBR-760 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide IR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Dormant Products
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Discontinued Products
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Product Development Milestones
Featured News & Press Releases
Oct 31, 2019: Ipsen presents data on Somatuline Autogel at ISPOR Europe 2019
Jul 12, 2019: Zucara Therapeutics secures grant from GlycoNet to expand and validate their Drug Therapy Model for Type 1 Diabetes to Type 2 Diabetes
Jun 24, 2019: Ipsen announces U.S. FDA approval for newly designed pre-filled syringe for Somatuline Depot (lanreotide)
May 24, 2019: New investigational clinical data for Ipsens oncology products including lanreotide acetate in 11 solid tumor types to be presented at 2019 ASCO Annual Meeting
May 24, 2019: Ipsen to present on Somatuline at 2019 ASCO Annual Meeting
May 21, 2019: Crinetics Pharmaceuticals initiates phase 1 study of CRN01941 for the treatment of neuroendocrine tumors
Mar 19, 2019: Crinetics Pharmaceuticals doses first patients in phase 2 clinical trials of CRN00808 for acromegaly
Mar 14, 2019: Crinetics Pharmaceuticals announces presentation on drug candidate CRN-00808 at ENDO2019
Mar 06, 2019: Ipsen to present improvements to Somatuline Autogel pre-filled syringe at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference
Feb 28, 2019: Ipsen to present new data on enhancement of patient care at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference
Oct 12, 2018: Ipsen to present data on Lanreotide at ESMO 2018
Oct 05, 2018: Ipsen presents data on Somatuline depot at the North American Neuroendocrine Tumor Society (NANETS) Annual Symposium
Jun 21, 2018: Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Acromegaly
Mar 12, 2018: Crinetics Pharmaceuticals Announces Upcoming Presentation on Acromegaly Drug Candiadate CRN00808 at ENDO 2018
Feb 13, 2018: Health Canada approves Ipsen Somatuline Autogel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Overview
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Companies Involved in Therapeutics Development
Amryt Pharma Plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Enteris BioPharma Inc
GlyTech Inc
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Takeda Pharmaceutical Co Ltd
Tiburio Therapeutics Inc
Zucara Therapeutics Inc
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Drug Profiles
AP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-00808 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-01941 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Edotreotide Labeled Yttrium 90 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR2 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBR-760 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide IR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Dormant Products
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Discontinued Products
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Product Development Milestones
Featured News & Press Releases
Oct 31, 2019: Ipsen presents data on Somatuline Autogel at ISPOR Europe 2019
Jul 12, 2019: Zucara Therapeutics secures grant from GlycoNet to expand and validate their Drug Therapy Model for Type 1 Diabetes to Type 2 Diabetes
Jun 24, 2019: Ipsen announces U.S. FDA approval for newly designed pre-filled syringe for Somatuline Depot (lanreotide)
May 24, 2019: New investigational clinical data for Ipsens oncology products including lanreotide acetate in 11 solid tumor types to be presented at 2019 ASCO Annual Meeting
May 24, 2019: Ipsen to present on Somatuline at 2019 ASCO Annual Meeting
May 21, 2019: Crinetics Pharmaceuticals initiates phase 1 study of CRN01941 for the treatment of neuroendocrine tumors
Mar 19, 2019: Crinetics Pharmaceuticals doses first patients in phase 2 clinical trials of CRN00808 for acromegaly
Mar 14, 2019: Crinetics Pharmaceuticals announces presentation on drug candidate CRN-00808 at ENDO2019
Mar 06, 2019: Ipsen to present improvements to Somatuline Autogel pre-filled syringe at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference
Feb 28, 2019: Ipsen to present new data on enhancement of patient care at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference
Oct 12, 2018: Ipsen to present data on Lanreotide at ESMO 2018
Oct 05, 2018: Ipsen presents data on Somatuline depot at the North American Neuroendocrine Tumor Society (NANETS) Annual Symposium
Jun 21, 2018: Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Acromegaly
Mar 12, 2018: Crinetics Pharmaceuticals Announces Upcoming Presentation on Acromegaly Drug Candiadate CRN00808 at ENDO 2018
Feb 13, 2018: Health Canada approves Ipsen Somatuline Autogel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amryt Pharma Plc, H2 2019
Pipeline by Crinetics Pharmaceuticals Inc, H2 2019
Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019
Pipeline by Enteris BioPharma Inc, H2 2019
Pipeline by GlyTech Inc, H2 2019
Pipeline by Ipsen SA, H2 2019
Pipeline by Progenics Pharmaceuticals Inc, H2 2019
Pipeline by Strongbridge Biopharma plc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Tiburio Therapeutics Inc, H2 2019
Pipeline by Zucara Therapeutics Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amryt Pharma Plc, H2 2019
Pipeline by Crinetics Pharmaceuticals Inc, H2 2019
Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019
Pipeline by Enteris BioPharma Inc, H2 2019
Pipeline by GlyTech Inc, H2 2019
Pipeline by Ipsen SA, H2 2019
Pipeline by Progenics Pharmaceuticals Inc, H2 2019
Pipeline by Strongbridge Biopharma plc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Tiburio Therapeutics Inc, H2 2019
Pipeline by Zucara Therapeutics Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Amryt Pharma Plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Enteris BioPharma Inc
GlyTech Inc
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Takeda Pharmaceutical Co Ltd
Tiburio Therapeutics Inc
Zucara Therapeutics Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Amryt Pharma Plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Enteris BioPharma Inc
GlyTech Inc
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Takeda Pharmaceutical Co Ltd
Tiburio Therapeutics Inc
Zucara Therapeutics Inc
